Form 4: Neurocrine Biosciences Chief Scientific Officer Exercises Options and Sells Shares Under Pre-Arranged Plan

Neurocrine Biosciences' Chief Scientific Officer, Jude Onyia, exercised stock options and subsequently sold 59,819 shares of common stock for a profit, as part of a pre-arranged Rule 10b5-1 trading plan.

Summary

• Jude Onyia, Chief Scientific Officer of Neurocrine Biosciences Inc. (NBIX), engaged in a pre-planned transaction on July 9, 2025.
• Exercised 59,819 non-qualified stock options at an exercise price of $84.74 per share.
• Concurrently sold 59,819 shares of common stock at a weighted average price of $130.455 per share.
• The sale was executed under a Rule 10b5-1 trading plan adopted on November 18, 2024.
• Following these transactions, Jude Onyia directly holds 18,289 shares of common stock and 35,268 non-qualified stock options.

Sentiment

Score: 6

Explanation: The transaction itself is neutral, being a pre-planned insider sale. The fact that the sale price is significantly higher than the exercise price is positive for the insider, but the sale of shares by a CSO could be viewed with slight caution by some investors, though mitigated by the 10b5-1 plan.

Positives

• The sale price of $130.455 per share is significantly higher than the option exercise price of $84.74, indicating a substantial gain for the insider on these shares.
• The transaction was conducted under a Rule 10b5-1 trading plan, which indicates a pre-scheduled, non-discretionary sale, often mitigating concerns about opportunistic insider selling.

Negatives

• A high-ranking officer selling a significant number of shares could be perceived negatively by some investors, even if pre-planned.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding the company's future performance or strategic direction. It solely reports an insider's equity transaction.

Management Comments

• The disposition was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2024.
• Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

Industry Context

This Form 4 filing details a routine insider equity transaction for a biotechnology company. Such transactions are common in the industry as executives monetize vested equity, often through pre-arranged plans to avoid accusations of trading on material non-public information. It does not provide specific insights into broader industry trends or competitive landscape.

Comparison to Industry Standards

• This document reports an insider transaction, which is a standard disclosure requirement for publicly traded companies across all industries.
• The use of a Rule 10b5-1 plan aligns with best practices for corporate governance, allowing insiders to sell shares without concerns of trading on inside information. There are no specific company or project results to compare to industry benchmarks in this filing.

Corporate Governance

Stakeholder Impact

• Shareholders: May observe a high-ranking executive monetizing vested equity, which could be interpreted neutrally as a routine event or slightly negatively as a reduction in insider holdings, though mitigated by the 10b5-1 plan.

Key Dates

Recommendation

Keywords

Neurocrine Biosciences, NBIX, Insider Trading, Form 4, Stock Option Exercise, Share Sale, Rule 10b5-1, Jude Onyia, Chief Scientific Officer, Biotechnology, Pharmaceuticals